Rimeporide

Rimeporide
Clinical data
ATC code
  • none
Legal status
Legal status
  • Experimental
Identifiers
IUPAC name
  • N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC11H15N3O5S2
Molar mass333.38 g·mol−1
3D model (JSmol)
SMILES
  • Cc1cc(c(cc1C(=O)NC(=N)N)S(=O)(=O)C)S(=O)(=O)C
InChI
  • InChI=1S/C11H15N3O5S2/c1-6-4-8(20(2,16)17)9(21(3,18)19)5-7(6)10(15)14-11(12)13/h4-5H,1-3H3,(H4,12,13,14,15)
  • Key:GROMEQPXDKRRIE-UHFFFAOYSA-N

Rimeporide is an experimental drug for the treatment of Duchenne muscular dystrophy, being developed by the EspeRare foundation.[1] it has been granted orphan drug status by the European Medicines Agency.[2]

Mechanism of action

The substance blocks an ion pump called sodium–hydrogen antiporter 1. While the exact mechanism is unknown, it is speculated that inhibition of this pump reduces pH, sodium and calcium overload in cells of patients with Duchenne muscular dystrophy.[1]

History

Rimeporide was designed as a treatment for chronic heart failure. It was tested in seven Phase I studies clinical trials in patients with congestive heart failure and some degree of renal insufficiency. Subsequently, the drug was licensed to EspeRare, a Swiss nonprofit organisation[3] that aims at repositioning drugs for rare diseases. As of May 2015, the substance has demonstrated efficacy in several animal models of Duchenne muscular dystrophy.[4]

It has also been recently tested in young boys with Duchenne muscular Dystrophy aged 6 to 11 years.[5]

See also

Other drugs for Duchenne muscular dystrophy

[6]

References

  1. 1 2 Spreitzer H (26 May 2015). "Neue Wirkstoffe – Rimeporid". Österreichische Apothekerzeitung (in German). 69 (11): 12.
  2. ↑ "EspeRare's Rimeporide receives Orphan Drug Designation in Duchenne Muscular Dystrophy". EspeRare. 4 May 2015.
  3. ↑ "Our mission and vision". EspeRare. Retrieved 23 July 2015.
  4. ↑ Ghaleh B, Barthélemy I, Wojcik J, Sambin L, Bizé A, Hittinger L, Tran TD, Thomé FP, Blot S, Su JB (August 2020). "Protective effects of rimeporide on left ventricular function in golden retriever muscular dystrophy dogs". International Journal of Cardiology. 312: 89–95. doi:10.1016/j.ijcard.2020.03.031. PMID 32199683.
  5. ↑ Previtali SC, Gidaro T, Díaz-Manera J, Zambon A, Carnesecchi S, Roux-Lombard P, Spitali P, Signorelli M, Szigyarto CA, Johansson C, Gray J, Labolle D, Porte Thomé F, Pitchforth J, Domingos J, Muntoni F (September 2020). "Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy". Pharmacological Research. 159: 104999. doi:10.1016/j.phrs.2020.104999. PMC 7482441. PMID 32535224.
  6. ↑ Ghaleh B, Barthélemy I, Wojcik J, Sambin L, Bizé A, Hittinger L, et al. (August 2020). "Protective effects of rimeporide on left ventricular function in golden retriever muscular dystrophy dogs". International Journal of Cardiology. 312: 89–95. doi:10.1016/j.ijcard.2020.03.031. PMID 32199683.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.